Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy

European Journal of Gynaecological Oncology

Volumn 25, Issue 1, 2004, Pages 90-92

  Mardesic, T ^a,b   Snajderova, M ^a   Sramkova, L ^a   Keslova, P ^a   Sedlacek, P ^a   Stary, J ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Sanatorium Pronatal   (Czech Republic)

Author keywords

Chemotherapy; GnRH analogues; Gonadotoxicity, Fertility

Indexed keywords

CETRORELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; TRIPTORELIN;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMALE; FEMALE FERTILITY; GONAD FUNCTION; GONADAL DISEASE; GONADOTROPIN RELEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOPHYSIS GONAD SYSTEM; RELIABILITY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; LUTEINIZING HORMONE; OVARIAN FAILURE, PREMATURE; PROSPECTIVE STUDIES; TRIPTORELIN;

EID: 0842285305     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Janson P.O.: "Possibilities of fertility preservation in children and young adults undergoing treatment for malignancy". Acta Obstet. Gynecol. Scand., 2000, 79, 240.
2. Blumenfeld Z., Avivi I., Ritter M., Rowe J.M.: "Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women". J. Soc. Gynecol. Invest., 1999, 6, 229.
3. Blumenfeld Z., Haim N.: "Prevention of gonadal damage during cytotoxic therapy". Ann. Med., 1997, 29, 199.
4. Glaser S.L.: "Reproductive factors in Hodgkin disease in women: a review". Am. J. Epidemiol., 1994, 139, 237.
5. Sutcliff S.B.: "Cytotoxic chemotherapy and gonadal function in patients with Hodgkin disease". JAMA, 1979, 242, 1898.
6. Broekmans F.J., Bernardus R.E., Broesers A.: "Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR". Clinical Endocrinology, 1993, 38, 579.
7. Coy D.H., Labrie F., Savary M.: "LH releasing activity of potent LH-RH analogues in vitro". Biochem. Biophys. Res. Comm., 1975, 65, 576.
8. Adashi E.Y.: "The ovarian follicular apparatus". In: Adashi E.Y., Rock J.A., Rosenwaks Z. (eds.). Reproductive Endocrinology, Surgery and Technology. Philadelphia, Lippincott Raven, 1996, 17.
9. Familiari G., Caggiati A., Nottola S.A., Ermini M., Di Bendetto M.R., Motta P.M.: "Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease". Hum. Reprod., 1993, 8, 2080.
10. Ataya K., Moghissi K.: "Chemotherapy induced premature ovarian failure: mechanisms and prevention". Steroids, 1989, 54, 607.
11. Bokser L., Szende B., Schally A.V.: "Protective effects of D-Trp6-LHRH microcapsules against cyclophosphamide-induced gonadotoxicity in female rats". Br. J. Cancer, 1990, 61, 861.
12. Ataya K., Rao L.V., Lawrence E., Kimmel R.: "Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys". Biol. Reprod., 1995, 52, 365.
13. Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N.: "Prevention of irreversible chemotherapy induced ovarian damage in young women with lymphoma by gonadotrophin-releasing hormone agonist in parallel to chemotherapy". Hum. Reprod., 1996, 11, 1620.